DRUG-INDUCED HEPATIC DISORDERS - INCIDENCE, MANAGEMENT AND AVOIDANCE

被引:38
作者
DOSSING, M
SONNE, J
机构
[1] Medical Department P, Bispebjerg Hospital, Copenhagen Nv, DK-2400
[2] Medical Department F, Gentofte Hospital, Hellerup
关键词
D O I
10.2165/00002018-199309060-00007
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Drug-induced liver injury has been associated with more than 800 different drugs, leading to hospital admission in 1 of 600 to 3500 admissions. This amounts to 2 to 3% of all hospitalisations due to adverse drug reactions, or about 3% of all jaundiced patients. The prognosis of clinically overt drug hepatotoxicity is relatively serious. The clinical picture is essentially nonspecific, with a highly variable latency period from days to years. Drug hepatotoxicity can mimic almost any kind of liver disease. A thorough drug history, a low threshold of suspicion and the exclusion of other causes of liver disease are important for the detection of drug-induced liver disorders. Treatment consists of discontinuation of suspected drug(s), acetylcysteine in the course of paracetamol (acetaminophen) toxicity, and liver transplantation in selected cases of fulminant liver failure. Guidelines regarding the use of selected drugs such as methotrexate and halothane should be followed. Potentially hepatotoxic drugs should be used cautiously in alcoholic patients with or without liver involvement. Patients with uncompensated liver disease should receive a reduced dose of drugs adjusted to the degree of liver function impairment. The general public should be warned against abuse of hepatotoxic drugs such as paracetamol and anabolic steroids.
引用
收藏
页码:441 / 449
页数:9
相关论文
共 59 条
  • [1] Anonymous, Report of an international consensus meeting. Drug-induced liver disorders: standardization of definitions and criteria of causality assessment of adverse drug reactions, International Journal of Clinical Pharmacology, Therapy and Toxicology, 28, pp. 317-322, (1990)
  • [2] Bass N.M., Willia R.L., Guide to drug dosage in hepatic disease, Clinical Pharmacokinetics, 15, pp. 396-420, (1988)
  • [3] Bernauau J., Rueff B., Benhamou J.P., Fulminant and subfulminant liver failure: definitions and causes, Seminars in Liver Disease, 6, pp. 97-106, (1986)
  • [4] Biour M., Poupon R., Grange J-D, Chazoulleres O., Levy V-G, Et al., Hepatotoxité des medicaments, Gastroenterologie Clinique et Biologique, 16, pp. 64-88, (1992)
  • [5] Bismuth H., Samuel D., Gugenheim J., Castaing D., Bernuau J., Et al., Emergency liver transplantation for fulminant hepatitis, Annals of Internal Medicine, 107, pp. 337-341, (1987)
  • [6] Bjorneboe M., Iversen O., Olsen S., Infective hepatitis and toxic jaundice in municipal hospital during a five-year period, Acta Medica Scandinavica, 182, pp. 491-501, (1967)
  • [7] Boekhorst T., Urlus M., Doesburg W., Yap S.H., Gorris R.J.A., Etiologic factors of jaundice in severely ill patients, Journal of Hepatology, 7, pp. 111-117, (1988)
  • [8] Bonacini M., Hepatobiliary complications in patients with human immunodeficiency virus infection, American Journal of Medicine, 92, pp. 404-411, (1992)
  • [9] Bottiger L.E., Furhoff A.K., Holmberg L., Fatal reactions to drugs, Acta Medica Scandinavica, 205, pp. 451-456, (1979)
  • [10] Archives of Internal Medicine, 134, pp. 219-233, (1974)